Clinical Scorecard: Revisiting the Urine Albumin-Creatinine Ratio: A Timeless Indicator in Modern Cardiovascular Risk Assessment
At a Glance
Category
Detail
Condition
Cardiovascular disease risk prediction and assessment
Key Mechanisms
Urine albumin-to-creatinine ratio (UACR) reflects systemic endothelial dysfunction and microvascular injury, core mechanisms underlying heart failure, atrial fibrillation, and coronary heart disease
Target Population
Adults, particularly older adults (>65 years), patients with hypertension, diabetes, obesity, or chronic kidney disease
Care Setting
Primary prevention and cardiology outpatient settings
Key Highlights
Longitudinal UACR trajectories over 5 and 10 years identify distinct risk patterns associated with increased incidence of heart failure, atrial fibrillation, coronary heart disease, and mortality.
High-risk UACR trajectories (sustained medium-to-high or rapid rise) are associated with significantly higher cardiovascular event risk, independent of baseline UACR levels.
Serial UACR measurements improve cardiovascular risk stratification beyond single-time-point assessments and correlate with biomarkers of myocardial injury and stress (NT-proBNP, hsTnT, interstitial myocardial fibrosis).
Guideline-Based Recommendations
Diagnosis
Use spot urine albumin-to-creatinine ratio (UACR) as a practical and reliable estimate of albuminuria, overcoming limitations of 24-hour urine collection.
Incorporate serial UACR measurements to detect dynamic changes and identify high-risk trajectories not apparent from baseline values.
Management
Employ renin–angiotensin–aldosterone system (RAAS) blockade to reduce albuminuria and mitigate cardiovascular risk.
Integrate UACR assessment into cardiovascular risk prediction models such as the American Heart Association’s PREVENT equation.
Recognize albuminuria as a modifiable risk factor warranting intensified monitoring and intervention, especially in patients with diabetes, hypertension, or chronic kidney disease.
Monitoring & Follow-up
Perform routine serial UACR measurements in cardiology practice to refine cardiovascular risk stratification.
Monitor associated biomarkers of myocardial injury and stress (NT-proBNP, hsTnT) to enhance risk assessment.
Risks
Single spot urine protein measurements may be unreliable due to variability from hydration, circadian rhythm, and physical activity.
High-risk UACR trajectories are more prevalent among males, non-White individuals, uninsured, less educated, smokers, and those with higher baseline blood pressure or BMI.
Patient & Prescribing Data
Patients with elevated or rising UACR, including those with normal baseline UACR but high-risk longitudinal trajectories
RAAS blockade remains a cornerstone therapy to reduce albuminuria and cardiovascular risk; early identification via serial UACR allows timely intervention.
Clinical Best Practices
Incorporate serial UACR measurements rather than relying on single-time-point assessments for cardiovascular risk prediction.
Use UACR alongside other biomarkers (NT-proBNP, hsTnT) to identify myocardial injury and stress, facilitating comprehensive risk stratification.
Recognize the shared pathophysiology of cardio–kidney–metabolic syndrome to guide multidisciplinary preventive strategies.
Target modifiable risk factors such as hypertension, diabetes, obesity, and smoking to reduce progression of albuminuria and cardiovascular risk.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
